National Cancer Institute; Notice of Meeting, 28358 [06-4561]
Download as PDF
<![CDATA[
sroberts on PROD1PC70 with NOTICES
28358
Federal Register / Vol. 71, No. 94 / Tuesday, May 16, 2006 / Notices
Inhibition of Cripto-1 may be associated
with inhibiting the progression of these
diseases via a disclosed method for
inhibiting the expression or downstream
signaling pathways mediated by Cripto1. This inhibition can be achieved
through the expression of various
inhibitory oligonucleotides.
Additionally, the development of
antibodies against Cripto-1 has already
been achieved for the detection of
Cripto-1 in human pathological
specimens.
It is estimated that by 2050, 14
million Americans will suffer from AD,
representing national annual costs for
caring and due to productivity lost of
approximately $160 billion. Despite
active research in this area, there
remains urgent need to identify
differentially expressed genes in and to
develop methods for detecting
neurodegenerative disease through
assaying expression levels of specific
genes. Currently, there are no drugs
directed at inhibiting Cripto-1 as a
therapeutic agent for AD or other
neurodegenerative diseases. This
invention holds the promise of market
opportunities through pursuing
development of Cripto-1 as a biomarker
for diagnosis of and possible target for
therapeutic intervention of these
diseases.
Inventors: David S. Salomon (NCI) et
al.
Publications:
1. CL Parish et al., ‘‘Cripto as a target
for improving embryonic stem cellbased therapy in Parkinson’s disease,’’
Stem Cells 2005 Apr; 23(4):471–476.
2. HB Adkins et al., ‘‘Antibody
blockade of the Cripto CFC domain
suppresses tumor cell growth in vivo,’’
J Clin Invest. 2003 Aug 15; 112(4): 575–
587.
Patent Status: U.S. Provisional
Application No. 60/508,750 filed 03 Oct
2003 (HHS Reference No. E–075–2003/
0–US–01); PCT Application No. PCT/
US04/32649 filed 01 Oct 2004 (HHS
Reference No. E–075–2003/0-PCT–02),
which published as WO 2005/033341
on 02 Jun 2005.
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Michelle A.
Booden, Ph.D.; 301/451–7337;
boodenm@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute,
Mammary Biology and Tumorigenesis
Laboratory, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this technology. Please
contact Jeffrey Hildesheim, Ph.D. at
(301) 435–1569 or
VerDate Aug<31>2005
16:06 May 15, 2006
Jkt 208001
hildesheimj@mail.nih.gov for more
information.
Dated: May 5, 2006.
David R. Sadowski,
Acting Director, Division of Technology
Development and Transfer, Office of
Technology Transfer, National Institutes of
Health.
[FR Doc. E6–7428 Filed 5–15–06; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the meeting of the
National Cancer Advisory Board.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
A portion of the meeting will be
closed to the public in accordance with
the provisions set forth in sections
552b(c)(4), and 552b(c)(6), as amended.
The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Advisory Board.
Open: June 14, 2006, 8 a.m. to 4:30 p.m.
Agenda: Program reports and
presentations; Business of the Board.
Place: National Cancer Institute, 9000
Rockville Pike, Building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
20892.
Contact Person: Dr. Paulette S. Gray,
Executive Secretary, National Cancer
Institute, National Institutes of Health, 6116
Executive Boulevard, 8th Floor, Room 8001,
Bethesda, MD 20892–8327. (301) 496–5147.
Name of Committee: National Cancer
Advisory Board.
Closed: June 14, 2006, 4:30 p.m. to
Adjournment.
Agenda: Review of grant applications.
Contact Person: Dr. Paulette S. Gray,
Executive Secretary, National Cancer
Institute, National Institutes of Health, 6116
Executive Boulevard, 8th Floor, Room 8001,
Bethesda, MD 20892–8327. (301) 496–5147.
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
Name of Committee: National Cancer
Advisory Board.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page:
deainfo.nci.nih.gov/advisory/ncab.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: May 9, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–4561 Filed 5–15–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; CA–07–
001, CA–07–007 (STTR), CA–07–006 (SBIR)
Innovation Technologies for the Molecular
Analysis of Cancer.
Date: June 15–16, 2006.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marriott Gaithersburg
Washingtonian Center, 9751 Washingtonian
Boulevard, Gaithersburg, MD 20878.
E:\FR\FM\16MYN1.SGM
16MYN1
]]>Agencies
[Federal Register Volume 71, Number 94 (Tuesday, May 16, 2006)]
[Notices]
[Page 28358]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-4561]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of
the National Cancer Advisory Board.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
A portion of the meeting will be closed to the public in accordance
with the provisions set forth in sections 552b(c)(4), and 552b(c)(6),
as amended. The grant applications and the discussions could disclose
confidential trade secrets or commercial property such as patentable
material, and personal information concerning individuals associated
with the grant applications, the disclosure of which would constitute a
clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Advisory Board.
Open: June 14, 2006, 8 a.m. to 4:30 p.m.
Agenda: Program reports and presentations; Business of the
Board.
Place: National Cancer Institute, 9000 Rockville Pike, Building
31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 20892.
Contact Person: Dr. Paulette S. Gray, Executive Secretary,
National Cancer Institute, National Institutes of Health, 6116
Executive Boulevard, 8th Floor, Room 8001, Bethesda, MD 20892-8327.
(301) 496-5147.
Name of Committee: National Cancer Advisory Board.
Closed: June 14, 2006, 4:30 p.m. to Adjournment.
Agenda: Review of grant applications.
Contact Person: Dr. Paulette S. Gray, Executive Secretary,
National Cancer Institute, National Institutes of Health, 6116
Executive Boulevard, 8th Floor, Room 8001, Bethesda, MD 20892-8327.
(301) 496-5147.
Name of Committee: National Cancer Advisory Board.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: deainfo.nci.nih.gov/advisory/ncab.htm, where an agenda and any
additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: May 9, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 06-4561 Filed 5-15-06; 8:45 am]
BILLING CODE 4140-01-M
